Literature DB >> 28161386

Podocyturia parallels proximal tubule dysfunction in type 2 diabetes mellitus patients independently of albuminuria and renal function decline: A cross-sectional study.

Ligia Petrica1, Mihaela Vlad2, Adrian Vlad3, Gheorghe Gluhovschi1, Florica Gadalean1, Victor Dumitrascu4, Roxana Popescu5, Cristina Gluhovschi1, Petru Matusz6, Silvia Velciov1, Flaviu Bob1, Sorin Ursoniu7, Daliborca Vlad4.   

Abstract

AIMS: Detection of podocytes in the urine of patients with type 2 diabetes may indicate severe injury to the podocytes. In the course of type 2 diabetes the proximal tubule is involved in urinary albumin processing. We studied the significance of podocyturia in relation with proximal tubule dysfunction in type 2 diabetes.
METHODS: A total of 86 patients with type 2 diabetes (34-normoalbuminuria; 30-microalbuminuria; 22-macroalbuminuria) and 28 healthy subjects were enrolled in the study and assessed concerning urinary podocytes, podocyte-associated molecules, and biomarkers of proximal tubule dysfunction. Urinary podocytes were examined in cell cultures by utilizing monoclonal antibodies against podocalyxin and synaptopodin.
RESULTS: Podocytes were detected in the urine of 10% of the healthy controls, 24% of the normoalbuminuric, 40% of the microalbuminuric, and 82% of the macroalbuminuric patients. In multivariate logistic regression analysis, urinary podocytes correlated with urinary albumin:creatinine ratio (p=0.006), urinary nephrin/creat (p=0.001), urinary vascular endothelial growth factor/creat (p=0.001), urinary kidney injury molecule-1/creat (p=0.003), cystatin C (p=0.001), urinary advanced glycation end-products (p=0.002), eGFR (p=0.001).
CONCLUSIONS: In patients with type 2 diabetes podocyturia parallels proximal tubule dysfunction independently of albuminuria and renal function decline. Advanced glycation end-products may impact the podocytes and the proximal tubule.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Advanced glycation end-products; Albuminuria; Podocyturia; Proximal tubule; Renal function

Mesh:

Year:  2017        PMID: 28161386     DOI: 10.1016/j.jdiacomp.2017.01.007

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  6 in total

Review 1.  Podocytes from the diagnostic and therapeutic point of view.

Authors:  Janina Müller-Deile; Mario Schiffer
Journal:  Pflugers Arch       Date:  2017-05-16       Impact factor: 3.657

2.  Urinary podocyte-associated mRNA levels correlate with proximal tubule dysfunction in early diabetic nephropathy of type 2 diabetes mellitus.

Authors:  Ligia Petrica; Sorin Ursoniu; Florica Gadalean; Adrian Vlad; Gheorghe Gluhovschi; Victor Dumitrascu; Daliborca Vlad; Cristina Gluhovschi; Silvia Velciov; Flaviu Bob; Petru Matusz; Oana Milas; Alina Secara; Anca Simulescu; Roxana Popescu
Journal:  Diabetol Metab Syndr       Date:  2017-05-06       Impact factor: 3.320

3.  Podocyturia: why it may have added value in rare diseases.

Authors:  Maria Dolores Sanchez-Niño; Maria Vanessa Perez-Gomez; Lara Valiño-Rivas; Roser Torra; Alberto Ortiz
Journal:  Clin Kidney J       Date:  2018-10-05

4.  Renal tubular Bim mediates the tubule-podocyte crosstalk via NFAT2 to induce podocyte cytoskeletal dysfunction.

Authors:  Chunmei Xu; Xiaojun Zhou; Tianyue Xie; Yuan Zhou; Qian Zhang; Shan Jiang; Rui Zhang; Lin Liao; Jianjun Dong
Journal:  Theranostics       Date:  2020-05-22       Impact factor: 11.556

5.  Risk factors and urinary biomarkers of non-albuminuric and albuminuric chronic kidney disease in patients with type 2 diabetes.

Authors:  Anton I Korbut; Vadim V Klimontov; Ilya V Vinogradov; Vyacheslav V Romanov
Journal:  World J Diabetes       Date:  2019-11-15

6.  Association between Renal Podocalyxin Expression and Renal Dysfunction in Patients with Diabetic Nephropathy: A Single-Center, Retrospective Case-Control Study.

Authors:  Rongzhen Wang; Can Yao; Feng Liu
Journal:  Biomed Res Int       Date:  2020-04-03       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.